TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04064788

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consecutive Modified Constraint-Induced Movement Therapy
Description: Consecutive mCIMT group received 6 hours per day mCIMT sessions for consecutive 10 days. Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
Study: NCT04448041

Intervention type: OTHER
Intervention: Malnutrition screening
Description: Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer

Intervention type: OTHER
Intervention: Malnutrition screening
Description: Primary comparison: Prevalence of malnutrition and impact on 30-day outcomes in patients undergoing surgery for cancer
Study: NCT03351309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone-based Cognitive Behavioral Therapy (CBT)
Description: Four session telephone CBT protocol.
Study: NCT04064788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physiotherapy
Description: Traditional physiotherapy within a specific program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Modified Constraint-Induced Movement Therapy
Description: Intermittent mCIMT group received mCIMT session 6 hours per day for 10 days, spread over 5 weeks (two days per week). Accompanied by a physiotherapist in 1 hour of the 6-hour restriction period, the family was guided within the remaining period and the activities were adapted to daily life.
Study: NCT02562833

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-Management and exercise
Description: Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Educational
Description: This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
Study: NCT03763864

Intervention type: OTHER
Group type: OTHER
Intervention: Skin Biopsy
Description: Skin Biopsy
Study: NCT02180230

Intervention type: DEVICE
Group type: OTHER
Intervention: Shorty implants
Description: Dental implant insertion to maxilla or mandible
Study: NCT01628549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg P005672-HCl
Description: P005672-HCl administered as an oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 mg P005672-HCl
Description: P005672-HCl administered as an oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dose-matched Placebo capsule administered as an oral capsule(s) once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched Placebo capsule administered as an oral capsule(s) once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg P005672-HCl
Description: P005672-HCl administered as an oral capsule(s) once daily
Study: NCT03209349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Water Exchange Sigmoidoscopy
Description: See arm description.
Study: NCT00215683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
Study: NCT02858011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash distribution during first 36 months
Description: Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash distribution during first 36 months
Description: Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cash distribution during first 36 months
Description: Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accompanying information sessions on health, child nutrition, household economics and education during first 36 months
Description: Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
Study: NCT00255021

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac
Description: 0.5 mL, IM
Study: NCT00359957

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pediatric Obesity Intervention (STANDARD)
Description: 14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
Study: NCT02858011

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accompanying information sessions on health, child nutrition, household economics and education during first 36 months
Description: Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Accompanying information sessions on health, child nutrition, household economics and education during first 36 months
Description: Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
Study: NCT00359957

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pediatric Obesity Intervention + High Activity (ADDED)
Description: 14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
Study: NCT02803294

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter aortic valve replacement
Study: NCT02994550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH/LH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH/LH
Study: NCT02967666

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FDG ligand
Study: NCT02858011

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preventive Nutrition Packages during last 12 months
Description: Fortified flour supplements for children (Supercereal Plus)and pregnant/lactating mothers (super Cereal)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cash distribution during the last 12 months
Description: Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months
Description: Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
Study: NCT02967666

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: DOTANOC ligand
Study: NCT03047733

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The XTRAC Excimer Laser System
Description: Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The XTRAC Excimer Laser System
Description: Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical tacrolimus 0.1% ointment
Description: Application of topical tacrolimus 0.1% ointment on the both lesions once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Description: Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
Study: NCT00508885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacinamide
Description: Niacinamide 250 mg twice daily titrated up to 750 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03668067

Intervention type: DEVICE
Intervention: 2WIN photoscreener
Description: conventional infrared off-axis photoscreener
Study: NCT05760690

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retro-Auricular Single-Site Endoscopic Thyroidectomy
Description: The strap muscles and the sternocleidomastoid muscle were separated. Upper parathyroid and lower parathyroid glands were identified and preserved. The recurrent laryngeal nerve (RLN) was identified，A lobe of thyroid specimen and central lymph nodes were dissected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transoral Endoscopic Thyroidectomy Vestibular Approach
Description: The patient was placed in a supine position with slight neck extension under nasotracheal intubation. The mouth was garbled with povidone iodine before surgery. Three laparoscopic ports (a 10- to 15-mm port at midline and two 5-mm ports at the lateral junction between the canine and first premolar teeth)were inserted under the lower lip at the oral vestibular area.The strap muscleswere separated in the midline to expose the thyroid and trachea. The recurrent laryngeal nerve (RLN) was identified at the insertion to the larynx, then followed downandparallel tothe trachea inferiorly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transareola Endoscopic Thyroidectomy
Description: The patient was in supine position. Incision was made inside the right areola and a 10mm puncture device was placed, subcutaneous separation rod was used to separate the space, and a 30° endoscope was introduced, puncture device was placed in a 5mm incision on the left areola, ultrasonic knife free flap was used, subcutaneous separation space was placed in the upper sternal segment, and a 5mm puncture device was placed outside the right areola. The anterior cervical flap was further dissociated to establish a space. The median cervical line was cut to cut off the isthmus of the thyroid, and the tracheal fascia ligament of the thyroid was separated and the nerve was exposed to protect the nerves. Then remove the lobe of thyroid and central lymph nodes
Study: NCT01772056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone, cream
Description: Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo,
Description: Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
Study: NCT02544282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Pecs II Block

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9%
Description: Placebo Pecs II block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: General Anesthesia
Study: NCT03710772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT02544282

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sevoflurane
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: General Anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: General Anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sufentanil
Description: General Anesthesia
Study: NCT03710772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT02544282

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atracurium
Description: General Anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atracurium
Description: General Anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Pain Relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paracetamol
Description: Pain Relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Pain Relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tramadol
Description: Pain Relief

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piritramide
Description: Pain Relief

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Piritramide
Description: Pain Relief
Study: NCT00241644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two or Three doses, oral administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two or Three doses, oral administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One or three doses, oral administration.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: One or three doses, oral administration.
Study: NCT01571778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Hygiene before Donning Non-sterile Gloves
Description: In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens~In the Experimental arm, they will be instructed to don gloves without washing their hands as described.
Study: NCT03332966

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychiatric questionnaires
Description: Participants will fill in the following questionnaires as part of routine intake assessments:~Generalised Anxiety Disorder Assessment (GAD-7); Mini-Social Phobia Inventory; Beck Depression Inventory 21A; Pittsburgh Sleep Quality Index; Insomnia Severity Index; Youth Experiences and Health Questionnaire; Adolescent Dissociative Experiences Scale (abbr.); Adolescent Peer Relations Instrument (APRI-B + cyberbullying, abbr.); Adolescent Trauma and Dissociation Scale (abbr.); Alcohol Use Disorders Identification Test; Alcohol, Smoking and Substance Involvement Screening Test - Lite (extended); Nicotine Questionnaire incl. Heavy Smoking Index; Internet Addiction Test (abbr.); European School Survey Project on Alcohol and Other Drugs 2015 Social Media Use and Computer Gaming; McMaster Family Assessment Device - General Functioning positive items; Multidimensional Scale of Perceived Social Support; Brief Resilience Scale; The Short Warwick-Edinburgh Mental Well-Being Scale

Intervention type: DIAGNOSTIC_TEST
Intervention: Semi-structured psychiatric interview
Description: Kiddie Schedule for Affective Disorders and Schizophrenia, version K-SADS-PL 2013.
Study: NCT04547543

Intervention type: OTHER
Group type: OTHER
Intervention: Videoconsultation
Description: Patient randomized on video-consultation group will have a video-consultation with the investigator within 3 months after the randomization. During this consultation, the investigator performs a clinical interrogation in order to collect anthropometric parameters: (sex, age, weight, height, body mass index (BMI)), blood pressure (by blood pressure monitor at home), the level of physical activity (by Actimetry over 7 days), smoking status and alcohol status
Study: NCT03710772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT02778308

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine + Cisplatin
Description: Day 1 and day 8 Gemcitabine Day 1 cisplatin
Study: NCT01572077

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FTHA, FDG PET imaging.
Description: Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
Study: NCT02317705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTL38

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near infrared camera imaging system
Description: Near infrared camera imaging system

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparotomy
Description: primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery
Study: NCT02800161

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trehalose
Description: Trehalose 70g/die

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Maltose
Description: Maltose 70g/die
Study: NCT06183047

Intervention type: DIAGNOSTIC_TEST
Intervention: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
Description: early release of chromogranin A (CgA) in patients with neuroendocrine tumours (NET) treated with peptide receptor radionuclide therapy (PRRT).
Study: NCT03710772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate
Description: Given IV
Study: NCT00763048

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Brush twice daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride, triclosan
Description: Brush twice daily
Study: NCT01179893

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: Intravenous immunoglobulin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PLEX
Description: Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
Study: NCT01598675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Same Belt Speeds
Description: 18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different Belt Speeds
Description: 18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Different Belt Speeds
Description: 18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
Study: NCT02289001

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on SBAR worksheet
Description: The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
Study: NCT02653534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
Study: NCT04439175

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taselisib
Description: Given PO
Study: NCT01032902

Intervention type: DEVICE
Intervention: In Vitro Diagnostic Device
Description: For the detection of antibodies to HIV in serum, plasma, blood and oral fluid

Intervention type: DEVICE
Intervention: In Vitro Diagnostic Device
Description: For the detection of antibodies to HIV in serum, plasma, blood and oral fluid

Intervention type: DEVICE
Intervention: In Vitro Diagnostic Device
Description: For the detection of antibodies to HIV in serum, plasma, blood and oral fluid